Log In
BCIQ
Print this Print this
 

X-396

  Manage Alerts
Collapse Summary General Information
Company Xcovery Holding Co. LLC
DescriptionAnaplastic lymphoma kinase (ALK) inhibitor
Molecular Target Anaplastic lymphoma kinase (ALK)
Mechanism of ActionAnaplastic lymphoma kinase (ALK) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
Regulatory Designation
PartnerBetta Pharmaceuticals Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/27/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today